Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Earnings Results, Beats Estimates By $0.07 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) posted its quarterly earnings data on Tuesday. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• Acumen said ALTITUDE-AD remains on track, with top-line Phase II results expected late in 2026 and enrollment/extension transitions proceeding smoothly. Management reiterated that the study is designed to test whether sabirnetug can deliver a differentiated effect by targeting toxic Abeta oligomers rather than amyloid plaques.
• The company highlighted a potentially favorable data package from ALTITUDE-AD, including the primary endpoint (iADRS) plus secondary efficacy, safety, ARIA, and biomarker readouts. Management said a “clear win” would likely require an efficacy signal around 30% slowing or better, along with a compelling risk-benefit profile versus approved anti-amyloid drugs.
• Acumen also emphasized progress in its enhanced brain delivery (EBD) program and said it expects to exercise its option to license two JCR Pharmaceuticals compounds in Q2 2026. The company continues to target an IND filing in mid-2027 and believes the platform could improve brain penetration, distribution, and enable subcutaneous dosing.
• The balance sheet ended the quarter at $128.4 million in cash and marketable securities, which management said should fund operations into early 2027. First-quarter operating results included $16.5 million of R&D expense, $4.7 million of G&A expense, and a $20.7 million net loss.
• Management said site feedback and operational execution on ALTITUDE-AD have been strong, including a relatively fast 10-month enrollment and improved screening using plasma p-tau217 to reduce unnecessary PET scans. They also noted continued physician and KOL interest in sabirnetug and the broader anti-amyloid market despite recent skepticism about the class.

Acumen Pharmaceuticals Stock Performance

Acumen Pharmaceuticals stock traded down $0.06 during trading hours on Thursday, hitting $2.43. The company had a trading volume of 64,672 shares, compared to its average volume of 682,907. The firm has a market cap of $175.59 million, a PE ratio of -1.31 and a beta of 0.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.07 and a quick ratio of 4.07. Acumen Pharmaceuticals has a one year low of $0.97 and a one year high of $3.60. The firm has a 50-day moving average of $2.75 and a 200 day moving average of $2.35.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ABOS shares. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Wednesday, April 8th. Finally, Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $105,000. Quadrature Capital Ltd acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $103,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $47,000. Marshall Wace LLP acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Acumen Pharmaceuticals by 12.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 49,062 shares of the company’s stock worth $104,000 after purchasing an additional 5,538 shares in the last quarter. Institutional investors and hedge funds own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.